The Inc. 5000 list is out — here's how Houston faired this year. Photo by Natalie Harms

One hundred businesses in the Houston area — including the top-ranked company in Texas — have been named to the 2024 Inc. 5000 list of the country’s fastest-growing private companies.

The 2024 Inc. 5000 ranks companies based on their percentage growth in revenue from 2020 to 2023.

Topping the list of Houston-area companies on the list is The Woodlands-based Segment HR, which notched revenue growth of 7,353 percent. That growth rate earned Segment HR the No. 32 spot on the national list and the No. 1 ranking in Texas.

Founded in 2018 by former federal HR specialist Robin Scott, Segment HR specializes in providing HR support for federal agencies. The company employs remote HR specialists in 23 states and the District of Columbia.

Here’s the list of the top 25 Houston-area companies in the 2024 edition of the Inc. 5000, including each company’s headquarters city, growth rate, and national ranking:

  • Segment HR, The Woodlands, 7,353 percent, No. 32
  • Dhanani Private Equity Group, Stafford, 3,617 percent, No. 89
  • Realty.com, Houston 3,052 percent, No. 107
  • Turtlebox Audio, Houston, 1,913 percent, No. 209
  • Amundson Group, Houston, 1,306 percent, No. 332
  • Valiant Business Lending, Houston, 1,286 percent, No. 337
  • Strategic Office Support, Houston, 1,192 percent, No. 367
  • 10xTravel, Houston, 1,102 percent, No. 401
  • NOW Insurance, Houston, 797 percent, No. 559
  • Explore Group, Houston, 796 percent, No. 562
  • Specialty1 Partners, Houston, 728 percent, No. 631
  • FINBOA, Houston, 714 percent, No. 650
  • BroCoTec, Houston, 687 percent, No. 690
  • Elite Roofing, Houston, 675 percent, No. 706
  • Patriot Bolt, Humble, 641 percent, No. 757
  • CT Sounds, Houston, 624 percent, No. 789
  • Supreme Jewelers, Friendswood, 525 percent, No. 965
  • Dometik Commercial Construction, Cypress, 477 percent, No. 1,070
  • Vape City, Houston, 459 percent, No. 1,116
  • Highlands Construction, Houston, 451 percent, No. 1,132
  • Houston Tents and Events, Houston, 438 percent, No. 1,171
  • Goebel Fasteners, Houston, 385 percent, No. 1,340
  • Field Industries, Houston, 376 percent, No. 1,366
  • Coverflex Manufacturing, Houston, 365 percent, No. 1,410

“One of the greatest joys of my job is going through the Inc. 5000 list,” says Mike Hofman, editor-in-chief of Inc. magazine. “To see all of the intriguing and surprising ways that companies are transforming sectors, from health care and AI to apparel and pet food, is fascinating for me as a journalist and storyteller.”

Elsewhere in Texas:

  • Austin-based Maev led the Austin-area pack with a growth rate of 6,734 percent, earning the No. 38 spot on the national list.
  • Dallas-based Archer Review led the Dallas-area pack with a growth rate of 5,771 percent, earning the No. 46 spot on the national list.
  • LaVernia-based Begesh led the San Antonio-area pack with a growth rate of 1,111 percent, earning the No. 396 spot on the national list.
The sweaters may be ugly, but the success of Specialty1's team is gorgeous. Specialty1/Facebook

Houston company boasting 18,000-percent growth scores top spot on coveted Inc. 5000 list

winner, winner

Dozens of Houston-based companies have undergone explosive growth in revenue over the last few years, with one such business landing near the top of the prestigious 2023 Inc. 5000 list.

One Houston-based company, Specialty1 Partners, ranked No. 15 nationally, boasting an unimaginable 18,747 percent growth rate from 2019 to 2022. Founded in 2019 by a group of doctors, Specialty1 Partners is a specialty dental services provider focusing on endodontics, oral surgery, and periodontics.

In a press release celebrating their No. 15 spot, the company says it now has more than 350 specialists across 27 states, and over 220 practices.

"We are honored to be recognized by Inc. 5000 for our 3rd consecutive year," stated Daryl Dudum, founder and co-CEO of Specialty1 Partners. "Our tremendous growth reflects our core mission in serving our dental surgical specialists by providing the clinical autonomy they deserve and the business support they need."

While being No. 1 in Houston, Specialty1 Partners is also the fifth highest-ranked Texas business on the list, and No. 1 in the national dental industry. Austin-based CharterUp, an online marketplace specializing in real-time instant transportation booking, ranked No. 2 nationally and No. 1 in the state.

It's not the first award that Specialty1 Partners is celebrating this year. Dudum and his co-founder and co-CEO, Matthew Hadda, were named regional winners for the 2023 EY Entrepreneurs of the Year awards.

Companies on the 2023 Inc. 5000, released August 15, are ranked by percentage growth in revenue from 2019 to 2022. To qualify for the list, a company must have been founded and generating revenue by March 31, 2019. The company also must have been U.S.-based, privately held, for-profit, and independent as of December 31, 2022. The minimum revenue required for 2019 was $100,000; the minimum for 2022 was $2 million.

In all, 482 Texas-based companies made this year’s list, and 95 of those are Houston-based. The report says eight businesses are newly-founded, 59 are repeat honorees, and more than 9,400 jobs were added thanks to these companies.

The 10 remaining Houston-area businesses ranking among the top 500 include:

  • No. 81 – Hawthorne Capital, 5,574 percent growth rate
  • No. 89 – Valiant Capital, 5,223 percent growth rate
  • No. 162 – Intervene K-12, 3,207 percent growth rate
  • No. 205 – Mission Driven Meat & Seafood, 2,720 percent growth rate
  • No. 292 – BODY20, 1,931 percent growth rate
  • No. 360 – Cobalt Engineering and Inspections, La Marque, 1,588 percent growth rate
  • No. 383 – Jess Lea Boutique, Magnolia, 1,519 percent growth rate
  • No. 393 – Gasochem International, 1,469 percent growth rate
  • No. 441 – Supreme Jewelers, Friendswood, 1,315 percent growth rate
  • No. 489 – Just Made Foods LLC, 1,198 percent growth rate

Here are the other Texas companies appearing in the state’s top 20 are:

  • No. 2 – CharterUp, Austin, 111,130 percent growth rate
  • No. 4 – Green Light Distribution, Coppell, 41,090 percent growth rate
  • No. 13 – Blue Hammer Roofing, Dallas, 19,510 percent growth rate
  • No. 14 – eTrueNorth, Mansfield, 19,130 percent growth rate
  • No. 19 – Publishing.com, Austin, 16,497 percent growth rate
  • No. 85 – Archer Review, Dallas, 5,378 percent growth rate
  • No. 90 – Norwood, Austin, 5,189 percent growth rate
  • No. 104 – 24HourNurse Staffing, Pittsburg, 4,520 percent growth rate
  • No. 110 – Advantis Medical Staffing, Dallas, 4,302 percent growth rate
  • No. 112 – CloudServus, Austin, 4,215 percent growth rate
  • No. 144 – Maveneer, Dallas, 3,630 percent growth rate
  • No. 145 – Ashland Greene, Dallas, 3,617 percent growth rate
  • No. 152 – Physical Therapy Biz, Dallas, 3,542 percent growth rate
  • No. 155 – Curis Functional Health, Dallas, 3,444 percent growth rate
  • No. 175 – TimelyCare, Fort Worth, 3,015 percent growth rate
  • No. 180 – LeasePoint Funding Group, Austin, 2,920 percent growth rate
The full list of businesses can be found on inc.com.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Baylor College of Medicine launches VC fund to invest in biotech startups

fresh funding

Houston’s Baylor College of Medicine just unveiled a new venture capital fund that backs early-stage biotech startups—and it’s already made its first investment.

BCM Legacy Fund I, funded by philanthropies, invested an undisclosed amount in Houston biotech startup Nemea Therapeutics. Nemea, a spinout of the Baylor College of Medicine and Germany’s Lead Discovery Center, is developing an oral drug to treat metastatic triple-negative breast cancer that no longer responds to currently available therapies.

This type of aggressive cancer spreads from the breast to other areas of the body, such as the bones, liver, lungs or brain. Roughly 38,000 to 57,000 Americans are diagnosed each year with metastatic triple-negative breast cancer. One study showed about half of patients survive past the one-year mark following diagnosis and about one-third survive two years.

“Baylor College of Medicine’s laboratories produce discoveries with the potential to change patients’ lives, and too many of them stall where academic funding ends and private investment has not yet begun,” Dr. Jakub Tolar, president, CEO and executive dean of the Baylor College of Medicine, said in a press release. “The BCM Legacy Fund fills that gap, giving our scientists a path to advance their discoveries to patients.”

The National Institutes of Health awards more than $36 billion per year for biomedical research in the U.S., Baylor said. But some biomedical discoveries “never leave the starting line because they don’t yet fit the economics of venture capital,” the college said.

“The forefront of a new model”

The BCM Legacy Fund aggregates philanthropic capital from private foundations and donor-advised funds. It then invests in startups so they can move beyond that starting line and into later-stage investment rounds. The Greater Houston Community Foundation is the fund’s philanthropic partner.

“It’s exciting to be on the forefront of a new model for philanthropic capital,” said Houston entrepreneur and investor Burton Hanson, managing partner of the fund.

“Not only do we hope to solve a real problem by advancing these therapies to the patients who need them most, but we also hope this model will inspire others in the city and beyond toward philanthropic creativity and a posture of ‘I sacrifice; we win.’”

The fund expects to invest in about 15 early-stage startups over a five-year span. Baylor declined to divulge the amount of money in the fund and the size of the investment in Nemea.

Nemea’s “world-class chemistry”

Hanson oversees the Baylor fund alongside Chicago investor Steve Lehmann, who led the University of Chicago’s Innovation Fund.

Lehmann said Nemea, the fund’s first portfolio company, “has world-class chemistry, Baylor biology, and patients with no good options. Our job is to fund the experiments that carry it to the next handoff, so that industry and later-stage investors can take it from there.”

Based at Houston’s massive Texas Medical Center, Nemea plans to start clinical trials next year in collaboration with Baylor’s Lester and Sue Smith Breast Center.

Nemea previously received $9 million from the Lead Discovery Center and a $1.6 million grant from Baylor. Last year, the startup said it was seeking $25 million to $30 million in seed and Series A funding.

Debra McCoy of Houston, a former managing director at BlackRock and former partner at Bain & Co., and Paul Thomas, co-founder and CEO of Spring-based benefits manager Luscinia Health, sit on the Baylor fund’s governing board. Dr. Paul Klotman, former president, CEO and executive dean of Baylor, is a senior strategic adviser.

How does the fund find investment targets?

The Baylor Legacy Fund relies on two tools to help unearth early-stage biotech startups:

  • High-resolution “innovation maps” of research institutions. These maps surface hidden clusters of innovation, identify rising-star researchers and tie pockets of “innovation supply” at Baylor to areas of “innovation demand” in biotech.
  • AI-enhanced due diligence. AI agents assist with due diligence of early-stage biotech startups. The fund says the platform “distills the frameworks we’ve developed over a decade of teaching and investing into a flexible … diligence environment.”

MD Anderson unveils $3.4B expansion with two new Houston cancer care facilities

major expansion

The cutting edge of cancer-fighting technology and science is getting even sharper after MD Anderson announced last week that it will open two new facilities in the Texas Medical Center within the next five years. Inspiration Tower and Prism will expand MD Anderson’s annual patient load in the TMC to 250,000 annually and will incorporate a variety of new techniques.

The $3.4 billion project will add 2 million square feet to MD Anderson's TMC footprint, bringing its total campus size to 22 million square feet by 2032. Located at the corner of Fannin Street and Holcombe Boulevard, the cancer center says the two new facilities will serve as its new "front door" to the TMC.

“Every detail of these buildings, from the technology to the treatment rooms, was designed around our patients who will receive their care in them and our employees who will work in them. The facilities will serve as a physical representation of hope for the patients and their families who will walk through the doors,” Dr. Jeffrey E. Lee, president ad interim of UT MD Anderson, said in a news release. “Inspiration Tower and Prism are the future of cancer care, and we are grateful for the longstanding support and guidance we’ve received from the UT System Board of Regents to bring these projects to life. These facilities are part of the most impactful capital expansion in UT MD Anderson’s history.”

Prism is especially exciting as it will represent fully half of the linear accelerator treatment in the TMC. Linear accelerator is a radiation treatment that uses magnetically charged fields to deliver targeted external radiation therapy, like shooting cancer with a rail gun. The treatment is safer and has fewer side effects than older radiation treatments.

In addition, Prism will contain 12 MRI machines, four CT scanners, two PET-CT units, 18 radiation vaults and seven radiation simulators. Patient comfort has also been put at a premium with multiple gardens and roof overlooks.

“Every patient we treat deserves an environment that reflects the excellence of the care they receive at UT MD Anderson,” Chris McKee, executive vice president and chief strategy officer at UT MD Anderson, added in the release. “Our new facilities will be innovative, agile, adaptable and beautiful, and they will allow us to care for more patients, more effectively – in an environment that enhances healing and well-being. We are building for our future and for every patient who will be counting on us.”

Prism is slated to open in 2030.

Inspiration Tower will have 25 floors of surgical, diagnostic, and treatment services. At 1.4 million square feet, it’s currently expected to be the largest cancer-specific treatment facility in the United States. The tower will be divided into units for specific types of cancer, making it easy to integrate the advancing research being done all over Houston.

Like Prism, Inspiration Tower is specifically designed to offer comfort and reassurance, with more garden space, terraces, and beautiful scenery to ease patient distress. It is expected to open in 2032.

Tesla will pull the plug on Cybertruck production at Texas factory in 2027

Tesla Talk

Tesla’s Cybertruck, the hulking, stainless-steel pickup that inspired devotion and derision with its science-fiction looks, will cease production next year.

CEO Elon Musk announced the model’s demise Friday, November 6, with a curt post on X, his social media site, simply noting production of the vehicle “will be winding down” around the middle of 2027 at its facility outside Austin, Texas. Musk said the move was to allow increased production of its Cybercab robotaxi.

For the Cybertruck, a pet project of Musk who insisted it was Tesla’s best product, it marks an unceremonious end to one of the auto industry’s most ballyhooed debuts.

“Few vehicles in history have generated as much attention,” said Armen Hareyan, whose Torque News site covers autos. “The Cybertruck became a cultural symbol – loved, mocked and impossible to ignore.”

The Cybertruck rolled onto the scene in a dramatic unveiling in 2019, when a Tesla designer hurled a metal ball at the vehicle to demonstrate its supposedly unbreakable glass, only to see it shatter. He repeated the stunt on another window of the truck only to shatter that one, too.

Even as some critics scoffed, Musk was steadfast.

“I just wanted to make a futuristic battle tank — something that looks like it could come out of ‘Blade Runner’ or ‘Aliens’ or something like that but was also highly functional,” he told Automotive News. He called it “a better sports car than a Porsche 911” and “a better truck than an F-150.”

It struck some as the perfect vehicular reflection of the brash, convention-busting Musk.

“A really controversial vehicle unveiled by a controversial individual into a market where none of the electric trucks have been able to really capture demand,” said Spencer Penn, a former Tesla executive who left the company before the Cybertruck’s launch and now heads software developer LightSource.

Penn remembered watching the unveiling and feeling initially revolted by the sight of the Cybertruck, calling its appearance “madness.” But the more he looked at it, the more his opinion changed. He signed up for a pre-sale reservation, though ended up not getting a Cybertruck when Musk’s promises of a price tag under $40,000 went unmet and the first trucks sold for double or more. Penn called the Cybertruck part of Tesla’s adventurous spirit that drives innovation.

“Some of these bets work and some of these bets don’t,” he said.

While the decision to end Cybertruck production may be driven by sales realities, it's also a reflection of Tesla’s shift to autonomous vehicles, on which Musk is betting the company’s future.

Musk once forecast he’d make 250,000 Cybertrucks a year. Kelley Blue Book estimated Tesla sold just 20,237 of the vehicles last year, down about half from the year prior. Sales through the end of September this year were down another 28%, according to Kelley Blue Book.

If the imposing, sharp-angled, dystopian appearance of the Cybertruck weren’t enough to turn many potential buyers away, Musk did so himself by allying with a panoply of right-wing figures, most notably U.S. President Donald Trump. He alienated some customers as his image morphed from eccentric innovator to polarizing force trading his billions for political influence.

Once-passionate Tesla drivers rushed to sell off their cars, or slapped stickers on the bumper declaring, “I bought this before Elon went crazy.” Organizers staged demonstrations outside Tesla showrooms and urged investors to dump shares of the company’s stock. Anger spilled into violence, with Molotov cocktails hurled at Tesla vehicles, charging stations set ablaze, and dealerships covered in graffiti.

Lovers of the Cybertruck became targets, too, subjected to shouts of “Nazi!” and extended middle fingers.

Ross Blankenship is one of them. When he first laid eyes on the Cybertruck, he felt transported to a world from his childhood, when he would play “Halo,” the sci-fi video game. He had to have it.

“I had that sort of child in me wanting to be part of something cool that would change the future of automotive,” Blankenship said in a call from his Cybertruck as he drove through Sunnyside, Colorado. Even as Blankenship found he agreed with Musk on politics, he hated seeing a vehicle he loved turned into a political symbol. “I never bought it for any other reason than the fascination with the future technology of trucks … so that was a little heartbreaking.”

He would buy another Cybertruck again in a heartbeat, calling its end “a sad moment.”